Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1937]

Zanubrutinib demonstrates superior PFS compared with ibrutinib for treatment of...

Dr Mazyar Shadman - Fred Hutchinson Cancer Center, Seattle, USA

Zanubrutinib demonstrates superior PFS compared with ibrutinib for treatment of R/R CLL and SLL ( Dr Mazyar Shadman - Fred Hutchinson Cancer Center, Seattle, USA )

PTCy/Tac/MMF gives a higher 1-year GVHD/relapse or progression-free survival...

Dr Monzr Al Malki - City of Hope, Duarte, USA

PTCy/Tac/MMF gives a higher 1-year GVHD/relapse or progression-free survival compared to Tac/MTX in graft-versus-host disease ( Dr Monzr Al Malki - City of Hope, Duarte, USA )

Effective treatment of low risk acute GVHD with itacitinib monotherapy

Prof Aaron Etra - The Tisch Cancer Institute, Mount Sinai, USA

Effective treatment of low risk acute GVHD with itacitinib monotherapy ( Prof Aaron Etra - The Tisch Cancer Institute, Mount Sinai, USA )

Optimisation of supportive, palliative and end of life care

Dr Zipporah Ali - Africa Organisation for Research & Training in Cancer, Kenya

Optimisation of supportive, palliative and end of life care ( Dr Zipporah Ali - Africa Organisation for Research & Training in Cancer, Kenya )

What is required to advance data ethics, data sharing, and Open Science across...

Dr Priya Kumari - Regional Cancer Centre Trivandrum, Trivandrum, India

What is required to advance data ethics, data sharing, and Open Science across LMICs ( Dr Priya Kumari - Regional Cancer Centre Trivandrum, Trivandrum, India )

Zanubrutinib improves PFS compared to ibrutinib for R/R chronic lymphocytic...

Dr Jennifer Brown - Dana-Farber Cancer Institute, Boston, USA

Zanubrutinib improves PFS compared to ibrutinib for R/R chronic lymphocytic leukaemia and small lymphocytic lymphoma ( Dr Jennifer Brown - Dana-Farber Cancer Institute, Boston, USA )

Add-on parsaclisib demonstrates improvement in symptoms and SV in MV patients...

Dr Abdulraheem Yacoub - University of Kansas Cancer Center, Kansas City, USA

Add-on parsaclisib demonstrates improvement in symptoms and SV in MV patients having a suboptimal response to ruxolitinib ( Dr Abdulraheem Yacoub - University of Kansas Cancer Center, Kansas City, USA )

Consolidation therapy with blinatumomab improves OS in newly diagnosed patients...

Dr Mark Litzow - Mayo Clinic, Rochester, USA

Consolidation therapy with blinatumomab improves OS in newly diagnosed patients with B-Lineage ALL in MRD negative remission ( Dr Mark Litzow - Mayo Clinic, Rochester, USA )

PTCy/Tac/MMF new standard for GVHD prophylaxis in reduced intensity conditioning

Dr Shernan Holtan - University of Minnesota, Minneapolis, USA

PTCy/Tac/MMF new standard for GVHD prophylaxis in reduced intensity conditioning ( Dr Shernan Holtan - University of Minnesota, Minneapolis, USA )

Acalabrutinib, venetoclax and obinutuzumab show high rates of clinical response...

Dr Christine Ryan - Dana-Farber Cancer Institute, Boston, USA

Acalabrutinib, venetoclax and obinutuzumab show high rates of clinical response in previously untreated CLL enriched for high-risk disease ( Dr Christine Ryan - Dana-Farber Cancer Institute, Boston, USA )

An analysis of the worldwide utilisation of haematopoietic stem cell...

Dr Molly Tokaz - Fred Hutchinson Cancer Center, Seattle, USA

An analysis of the worldwide utilisation of haematopoietic stem cell transplantation for acute myeloid leukaemia ( Dr Molly Tokaz - Fred Hutchinson Cancer Center, Seattle, USA )

Polatuzumab vedotin combined with R-ICE as second-line therapy gives favourable...

Dr Matthew Matasar - Rutgers Cancer Institute, New Brunswick, USA

Polatuzumab vedotin combined with R-ICE as second-line therapy gives favourable results against R/R diffuse large B-cell lymphoma ( Dr Matthew Matasar - Rutgers Cancer Institute, New Brunswick, USA )

More from ecancer